Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire) 16.03.21 Bintrafusp alfa, a drug to fight lung cancer that is in the late stages of development, did not show any benefit over a rival drug in trials. About Bintrafusp Alfa Bintrafusp alfa (M7824), discovered in-house at Merck, and currently in clinical development through a strategic alliance with GSK, is a potential first-in-class investigational bifunctional fusion protein designed to simultaneously block two immunosuppressive pathways, TGF-β and PD-L1, within the tumor microenvironment. In January, cancer hopeful bintrafusp alfa failed a key late-stage trial, and another drug in the company’s oncology pipeline, dostarlimab, suffered an inspection delay. Meanwhile, some investors will take interest in PD-1/cytokine combos given the recent blow-up of Merck KGaA/Glaxosmithkline’s bintrafusp alfa, an anti-PD-L1/TGF-β trap bispecific.
Federal Government Channel, Cool Places To Park And Chill Near Me, The Suffering: Ties That Bind Morality, Cities In Cass County, Michigan, National Championship Predictions Espn, Vibe Kayaks Sea Ghost 130 Canada, Vacation Home Rentals In Tarpon Springs Florida, Heathrow Sustainability Report 2019, The Lighthouse Radio Station,